Den intravitreale injektionsprocedure er forbundet med en lille risiko for endophtalmitis; i kliniske studier med Macugen er incidensen af endophtalmitis 0, 1% pr. injektion.
Intravitreal injection procedures are associated with a risk of endophthalmitis; in Macugen clinical trials, the incidence of endophthalmitis was 0.1% per injection.